Financial Statements and

(d) Exhibits

Reference is made to the Exhibit Index included with this Current Report on Form 8-K/A.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDL BIOPHARMA, INC.

(Company)

By:

/s/ John P. McLaughlin

John P. McLaughlin

President and Chief Executive Officer

Dated:

August3, 2016

Exhibit Index

Exhibit No.

Description

2.1*

Asset Purchase Agreement dated May 24, 2016, by and between Novartis AG, Novartis Pharma AG, Speedel Holding AG, and Noden Pharma DAC, a majority owned subsidiary of the Company.

99.1

Press Release issued by PDL BioPharma, Inc. on May 24, 2016. (Previously furnished with Original 8-K)

*

Schedules omitted pursuant to item 601(b)(2) of Regulation S-K. PDL Biopharma agrees to furnish supplementally a copy of any omitted schedule to the SEC upon its request.

Certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request under 17 C.F.R. Sections 200.80(b)(4) and 24b-2.

makes a similar move, sign up!

Other recent filings from the company include the following:

Departure of Directors or Certain - June 14, 2018
PDL BioPharma director just picked up 54,348 shares - June 12, 2018
PDL BioPharma director just picked up 54,348 shares - June 12, 2018
PDL BioPharma's CEO was just granted 1,922,100 options - June 12, 2018
PDL BioPharma director just picked up 54,348 shares - June 12, 2018

Auto Refresh

Feedback